Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIM AIM ImmunoTech	$2.65 +3.1%	$7.21	$2.46 ▼ $39.95	$2.03M	0.88	66,464 shs	54,241 shs
CRDL Cardiol Therapeutics	$1.31 -2.2%	$1.34	$0.77 ▼ $2.63	$109.66M	1.05	1.12 million shs	2.20 million shs
DNA Ginkgo Bioworks	$13.16 +2.0%	$11.21	$5.00 ▼ $16.85	$780.26M	1.5	1.85 million shs	1.33 million shs
VBV VBI Vaccines		C$0.00	C$3.85 ▼ C$7.60	C$308.86M	N/A	3,637 shs	1,300 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIM AIM ImmunoTech	0.00%	+6.00%	-69.38%	-71.01%	-90.19%
CRDL Cardiol Therapeutics	0.00%	+32.87%	+10.08%	+18.02%	-34.17%
DNA Ginkgo Bioworks	0.00%	+7.69%	+34.88%	+66.12%	-13.42%
VBV VBI Vaccines	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIM AIM ImmunoTech	1.3699 of 5 stars	3.5	0.0	0.0	0.0	2.0	0.0	0.0
CRDL Cardiol Therapeutics	2.5634 of 5 stars	3.7	2.0	0.0	0.0	3.9	0.0	0.6
DNA Ginkgo Bioworks	0.9579 of 5 stars	1.2	3.0	0.0	0.0	1.7	2.5	0.6
VBV VBI Vaccines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIM AIM ImmunoTech	3.00	Buy	$275.00	10,277.36% Upside
CRDL Cardiol Therapeutics	3.33	Buy	$8.00	510.69% Upside
DNA Ginkgo Bioworks	2.33	Hold	$8.50	-35.41% Downside
VBV VBI Vaccines	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CRDL, DNA, AIM, and VBV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/8/2025	DNA Ginkgo Bioworks	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/2/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIM AIM ImmunoTech	$146K	13.87	N/A	N/A	$0.20 per share	13.25
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.22 per share	N/A
DNA Ginkgo Bioworks	$230.82M	3.38	N/A	N/A	$10.35 per share	1.27
VBV VBI Vaccines	C$3.36M	0.00	N/A	N/A	C$1.01 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIM AIM ImmunoTech	-$28.96M	-$24.68	N/A	N/A	N/A	-12,594.21%	-421.73%	-147.54%	N/A
CRDL Cardiol Therapeutics	-$26.77M	-$0.34	N/A	N/A	N/A	N/A	-213.39%	-150.42%	N/A
DNA Ginkgo Bioworks	-$547.03M	-$5.86	N/A	N/A	N/A	-136.56%	-43.25%	-22.29%	N/A
VBV VBI Vaccines	N/A	-C$0.97	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest CRDL, DNA, AIM, and VBV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	CRDL Cardiol Therapeutics	-$0.11	-$0.07	+$0.04	-$0.07	N/A	N/A
8/7/2025	Q2 2025	DNA Ginkgo Bioworks	-$1.44	-$1.10	+$0.34	-$1.10	$41.60 million	$49.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIM AIM ImmunoTech	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
VBV VBI Vaccines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIM AIM ImmunoTech	0.05	0.75	0.75
CRDL Cardiol Therapeutics	0.01	3.26	3.26
DNA Ginkgo Bioworks	N/A	5.41	4.88
VBV VBI Vaccines	14.29	2.64	2.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIM AIM ImmunoTech	12.02%
CRDL Cardiol Therapeutics	12.49%
DNA Ginkgo Bioworks	78.63%
VBV VBI Vaccines	N/A

Insider Ownership

Company	Insider Ownership
AIM AIM ImmunoTech	0.02%
CRDL Cardiol Therapeutics	5.25%
DNA Ginkgo Bioworks	9.72%
VBV VBI Vaccines	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIM AIM ImmunoTech	20	764,000	68.74 million	Not Optionable
CRDL Cardiol Therapeutics	20	83.71 million	79.32 million	Not Optionable
DNA Ginkgo Bioworks	640	59.20 million	53.45 million	Optionable
VBV VBI Vaccines	22	64.08 million	N/A	Not Optionable

CRDL, DNA, AIM, and VBV Headlines

Recent News About These Companies

Decades of research push cytomegalovirus vaccine closer to reality

January 7, 2025 | msn.com

Five Covid-19 vaccine false theories - debunked

October 26, 2024 | bbc.co.uk

VBIVQ VBI Vaccines Inc.

August 15, 2024 | seekingalpha.com

VBI Vaccines Inc. (Nasdaq: VBIV) Rises from the Ashes and is NASDAQ Top Percentage Gainer

August 6, 2024 | investorideas.comI

VBI Vaccines Starts Restructuring Procedure in Canada

July 30, 2024 | marketwatch.com

VBI Vaccines secures court protection as it restructures, seeks buyer(s)

July 30, 2024 | fiercebiotech.comF

VBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023

April 16, 2024 | msn.com

VBI Vaccines sells hepatitis B vaccine candidate, manufacturing digs to partner Brii Biosciences for up to $33 million

February 14, 2024 | fiercepharma.comF

The Truth About Vaccines

January 6, 2024 | webmd.comW

VBI Vaccines Inc VBIV

October 31, 2023 | morningstar.comM

Access to new Covid-19 vaccines delayed for Vermonters on Medicaid

September 27, 2023 | vtdigger.orgV

No, Pfizer COVID-19 vaccine doesn't cause 'VAIDS.' That's not a real condition | Fact check

September 26, 2023 | usatoday.com

Availability of new 2023–2024 COVID-19 vaccine in Virginia

September 26, 2023 | newsleader.comN

The Consumer’s Guide to RSV Vaccines for Older Adults

September 24, 2023 | everydayhealth.comE

Updated COVID-19 vaccine recommended for everyone; old, young, immunocompromised will benefit most

September 23, 2023 | usatoday.com

Is It Safe to Get Multiple Vaccines at the Same Time?

September 22, 2023 | everydayhealth.comE

The real data behind the new COVID vaccines the White House is pushing

September 21, 2023 | nypost.comN

New COVID vaccines will be available in RI. Here's how to get one.

September 20, 2023 | providencejournal.comP

COVID vaccine pill that kills virus before it infects the body could be coming

September 15, 2023 | nypost.comN

Interim results show Brii’s therapeutic HBV vaccine induces immune response

September 8, 2023 | bioworld.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CRDL, DNA, AIM, and VBV Company Descriptions

AIM ImmunoTech NYSE:AIM

$2.65 +0.08 (+3.11%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.66 +0.01 (+0.38%)

As of 08/15/2025 07:50 PM Eastern

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Cardiol Therapeutics NASDAQ:CRDL

$1.31 -0.03 (-2.24%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.32 +0.00 (+0.38%)

As of 08/15/2025 07:55 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Ginkgo Bioworks NYSE:DNA

$13.16 +0.26 (+2.02%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$13.10 -0.05 (-0.42%)

As of 08/15/2025 07:43 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

VBI Vaccines TSE:VBV

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time